Eager To Counter Patent Cliff, Falling Share Price, Pfizer Forges New Partnerships Around The World, Inside China
This article was originally published in PharmAsia News
Executive Summary
BEIJING - The New York-headquartered Pfizer Inc. entered into an agreement with the Osaka-based Takeda Pharmaceutical to co-promote Takeda's diabetes drug Actos (pioglitazone) inside China in part because the American outfit can rely on its vastly expanded sales network here following its merger with Wyeth
You may also be interested in...
Pfizer Lowers Targeted Revenues For 2012; Wall Street Remains Skeptical
With the Wyeth integration well under way, Pfizer did what analysts claimed it was going to do for months - it lowered its 2012 revenue targets to $66 billion-$68.5 billion from $70 billion, the figure it initially projected when it announced the Wyeth merger a year ago. But these figures still tower above Wall Street's expectations
Pfizer Lowers Targeted Revenues For 2012; Wall Street Remains Skeptical
With the Wyeth integration well under way, Pfizer did what analysts claimed it was going to do for months - it lowered its 2012 revenue targets to $66 billion-$68.5 billion from $70 billion, the figure it initially projected when it announced the Wyeth merger a year ago. But these figures still tower above Wall Street's expectations
Pfizer Lowers Targeted Revenues for 2012; Wall Street Remains Skeptical
Pfizer's touts growth plans in emerging markets as the pharma prepares for the onset of Lipitor generics.